Efficacy Evaluation of SARVONUTRA M as Male Wellness Agent

Double Blind Placebo Controlled Study to Evaluate Efficacy of Innovative Natural Formulation (Sarvonutra M) to Enhance Performance, Endurance Conjugal Life, and Quality of Life in Men

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042708

Enrollment

Registered

2022-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N538- Other male sexual dysfunction

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: a) Healthy male individuals. b) Infertility and low conjugal life for more than 3 months diagnosed with oligospermia (defined by c) No past history of renal, hepatic, or any other chronic illness in the past d) Normal liver, and renal function tests. e) Patients freely willing and able to provide written informed consent, willing to follow study procedures.

Exclusion criteria

Exclusion criteria: a) Complete azoospermia in the pre-treatment samples b) Any congenital anomaly resulting in oligospermia c) Evidence of male accessory gland infection d) Any recent medical or surgical illness e) Hormone/any other treatment for promoting fertility in the last three months

Design outcomes

Primary

Measure	Time frame
a) Evaluate the improvements of quality of conjugal life. b) Reduction in premature ejaculation c) Arousal with lesser foreplay d) Improvement in seminal output and motility e) If any conceptions during clinical trialTimepoint: 6 - 8 weeks	—

Secondary

Measure	Time frame
a) Changes in mood swing b) Better sleep c) Improvement in Conjugal Life & WellbeingTimepoint: 6 - 8 weeks	—

Countries

India

Contacts

Public ContactDR SRINIVASA

SARVOTHAM CARE LIMITED

dr.mishra@sarvothamcare.com7975843079

Outcome results